Barclays PLC Ironwood Pharmaceuticals Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 416,320 shares of IRWD stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

416,320

Previous 416,320 -0.0%

Holding current value

$1.47 Million

Previous $1.72 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.93 - $7.04 $861,864 - $1.54 Million	219,304 Added 111.31%	416,320 $1.72 Million
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $520,217 - $802,701	-93,229 Reduced 32.12%	197,016 $1.29 Million
Q1 2024 May 15, 2024	SELL	$8.32 - $15.45 $2.18 Million - $4.05 Million	-262,323 Reduced 47.47%	290,245 $2.53 Million
Q4 2023 Feb 15, 2024	SELL	$8.79 - $11.51 $229,454 - $300,457	-26,104 Reduced 4.51%	552,568 $6.32 Million
Q3 2023 Nov 07, 2023	BUY	$8.25 - $11.35 $1.02 Million - $1.41 Million	123,874 Added 27.24%	578,672 $5.57 Million
Q2 2023 Aug 03, 2023	BUY	$10.1 - $11.6 $1.23 Million - $1.41 Million	121,785 Added 36.57%	454,798 $4.84 Million
Q1 2023 May 04, 2023	SELL	$10.37 - $12.56 $1.48 Million - $1.8 Million	-143,186 Reduced 30.07%	333,013 $3.5 Million
Q4 2022 Feb 13, 2023	SELL	$9.9 - $12.43 $973,130 - $1.22 Million	-98,296 Reduced 17.11%	476,199 $5.9 Million
Q3 2022 Nov 03, 2022	BUY	$10.14 - $12.38 $4.6 Million - $5.62 Million	453,988 Added 376.73%	574,495 $5.95 Million
Q2 2022 Aug 12, 2022	SELL	$11.05 - $12.72 $3.71 Million - $4.27 Million	-335,591 Reduced 73.58%	120,507 $1.39 Million
Q1 2022 May 16, 2022	BUY	$10.61 - $12.88 $2.48 Million - $3.01 Million	233,894 Added 105.26%	456,098 $5.74 Million
Q4 2021 Feb 14, 2022	BUY	$10.86 - $13.95 $70,459 - $90,507	6,488 Added 3.01%	222,204 $2.59 Million
Q3 2021 Nov 09, 2021	SELL	$11.92 - $13.92 $114,896 - $134,174	-9,639 Reduced 4.28%	215,716 $2.82 Million
Q2 2021 Aug 13, 2021	SELL	$10.16 - $13.11 $2.21 Million - $2.85 Million	-217,046 Reduced 49.06%	225,355 $2.9 Million
Q1 2021 May 13, 2021	BUY	$9.04 - $11.86 $589,163 - $772,951	65,173 Added 17.28%	442,401 $4.95 Million
Q4 2020 Feb 11, 2021	SELL	$9.05 - $12.2 $1.03 Million - $1.39 Million	-114,182 Reduced 23.24%	377,228 $4.3 Million
Q3 2020 Nov 12, 2020	BUY	$8.99 - $10.74 $1.93 Million - $2.3 Million	214,377 Added 77.38%	491,410 $4.42 Million
Q2 2020 Aug 12, 2020	BUY	$9.14 - $11.97 $425,604 - $557,383	46,565 Added 20.2%	277,033 $2.86 Million
Q1 2020 May 13, 2020	BUY	$8.58 - $14.01 $537,554 - $877,754	62,652 Added 37.33%	230,468 $2.33 Million
Q4 2019 Feb 10, 2020	BUY	$8.22 - $14.0 $580,882 - $989,338	70,667 Added 72.74%	167,816 $2.23 Million
Q3 2019 Nov 14, 2019	SELL	$8.59 - $10.96 $445,640 - $568,593	-51,879 Reduced 34.81%	97,149 $833,000
Q2 2019 Aug 14, 2019	SELL	$9.8 - $12.89 $918,965 - $1.21 Million	-93,772 Reduced 38.62%	149,028 $1.63 Million
Q1 2019 May 15, 2019	BUY	$8.27 - $12.73 $504,809 - $777,051	61,041 Added 33.58%	242,800 $3.29 Million
Q4 2018 Feb 14, 2019	BUY	$7.8 - $16.13 $895,603 - $1.85 Million	114,821 Added 171.53%	181,759 $1.88 Million
Q3 2018 Nov 14, 2018	BUY	$14.31 - $17.65 $812,650 - $1 Million	56,789 Added 559.55%	66,938 $1.24 Million
Q2 2018 Aug 14, 2018	SELL	$11.83 - $16.2 $272,456 - $373,102	-23,031 Reduced 69.41%	10,149 $194,000
Q1 2018 May 15, 2018	SELL	$11.13 - $13.63 $1.35 Million - $1.65 Million	-120,993 Reduced 78.48%	33,180 $511,000
Q4 2017 Feb 14, 2018	BUY	$12.16 - $14.58 $1.81 Million - $2.17 Million	149,073 Added 2923.0%	154,173 $2.31 Million
Q3 2017 Nov 14, 2017	BUY	$12.07 - $14.87 $61,557 - $75,837	5,100	5,100 $80,000

Others Institutions Holding IRWD

# of Institutions

238

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account